Telix Pharmaceuticals Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
FY EPS (est.)
$0.07next fiscal year
Monitoring Framework
Key Performance Indicators
Group Revenue Annually804MTarget: 950000000 to 970000000
Precision Medicine Segment Revenue Annually
R&D Investment Annually171.2MTarget: US$200 million to US$240 million
Watch Items
- FDA PDUFA decision date for Pixclara (TLX101-Px) brain cancer imaging agentTrigger: September 11, 2026Action: Monitor FDA announcement and prepare commercial launch strategy upon approval
- FDA clearance for Zircalix kidney cancer imaging candidateTrigger: Regulatory approval decisionAction: Track response to FDA request for additional data and prepare for market entry
- Phase 3 ProstACT Global trial progressionTrigger: Transition to randomized stageAction: Review clinical data updates and patient enrollment milestones across global sites
Research as of 19 Jun 2026